Esperion Therapeutics (ESPR) Convertible Debt (2020 - 2025)
Historic Convertible Debt for Esperion Therapeutics (ESPR) over the last 6 years, with Q3 2025 value amounting to $97.1 million.
- Esperion Therapeutics' Convertible Debt fell 6305.82% to $97.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $97.1 million, marking a year-over-year decrease of 6305.82%. This contributed to the annual value of $96.7 million for FY2024, which is 6301.74% down from last year.
- According to the latest figures from Q3 2025, Esperion Therapeutics' Convertible Debt is $97.1 million, which was down 6305.82% from $97.0 million recorded in Q2 2025.
- In the past 5 years, Esperion Therapeutics' Convertible Debt registered a high of $272.5 million during Q3 2021, and its lowest value of $96.7 million during Q4 2024.
- Over the past 5 years, Esperion Therapeutics' median Convertible Debt value was $260.3 million (recorded in 2023), while the average stood at $227.9 million.
- Its Convertible Debt has fluctuated over the past 5 years, first skyrocketed by 4399.53% in 2021, then tumbled by 6305.82% in 2025.
- Over the past 5 years, Esperion Therapeutics' Convertible Debt (Quarter) stood at $258.3 million in 2021, then increased by 0.63% to $259.9 million in 2022, then rose by 0.65% to $261.6 million in 2023, then plummeted by 63.02% to $96.7 million in 2024, then increased by 0.4% to $97.1 million in 2025.
- Its Convertible Debt was $97.1 million in Q3 2025, compared to $97.0 million in Q2 2025 and $96.9 million in Q1 2025.